Lead Product(s): PLX-R18
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel. Other factors included BARDA’s current strategic needs, availability of funds and resources.